Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biomedical Catalyst Feasibility Award to Tackle Drug-resistant Ovarian Cancer

Published: Tuesday, September 17, 2013
Last Updated: Tuesday, September 17, 2013
Bookmark and Share
Feasibility award granted by Technology Strategy Board to identify DUBs.

MISSION Therapeutics has been granted a Biomedical Catalyst Feasibility Award by the Technology Strategy Board to support the identification of DUBs required for the survival of drug-resistant ovarian cancers.

Ovarian cancer is the fifth most common cancer in women and is responsible for more deaths per year than any other cancer of the female reproductive system.

Unfortunately, development of drug resistance remains the main limitation of current chemotherapies for ovarian cancer.

Identifying novel targets and therapies tailored for treating drug-resistant ovarian cancer is thus an area of clear unmet clinical need.

Using an innovative approach, MISSION will identify novel DUB targets by exploiting the very changes in tumours that led to the development of drug resistance.

Commenting on the announcement, Dr Niall Martin, MISSION Chief Operating Officer, said: “The decision of the Technology Strategy Board to support our work shows the potential the DUB space holds for treating cancer. The funds from this Feasibility Award will be used to screen all known DUBs to find those which are suitable targets for our drug development programmes.”

The project will see MISSION identify DUB targets whose inhibition selectively kills drug-resistant ovarian tumours or re-sensitizes them to chemotherapy.

The most promising targets will enter MISSION’s pipeline for further drug discovery efforts with a view to developing new therapeutic agents for ovarian cancer.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MISSION Secures £20 million ($32 million) in Series B Financing
Pfizer Venture Investments join MISSION investor syndicate to advance compounds through preclinical development for genetically-defined cancers.
Tuesday, November 19, 2013
Appointment of Associate Faculty Member at Sanger Institute
MISSION Co-Founder and CSO, Professor Steve Jackson appointed as Faculty Member.
Monday, April 08, 2013
MISSION Therapeutics Strengthens Board
Appointments of Michael Moore and Fritz Frickel as Executive Chairman and Non-Executive Director respectively.
Monday, October 01, 2012
Scientific News
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Enzyme Links Age-Related Inflammation, Cancer
Researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration.
Viral Gene Editing System Corrects Genetic Liver Disease
Penn study has implications for developing safe therapies for an array of rare diseases via new gene cut-and-paste methods.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Curing Disease by Repairing Faulty Genes
New delivery method boosts efficiency of CRISPR genome-editing system.
'Junk' DNA Plays Role in Preventing Breast Cancer
Supposed "junk" DNA, found in between genes, plays a role in suppressing cancer, according to new research by Universities of Bath and Cambridge.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!